SIMON REDMON: Open Payments
NPI 1528176807 · SEMINARY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$308 in 15 payments from 7 companies in 2025. Trend: 2023 $327 · 2024 $120 · 2025 $308
Food & beverage: $308
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $150 |
| Novo Nordisk Inc | 3 | $51 |
| PFIZER INC. | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Exact Sciences Corporation | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Amgen Inc. | 1 | $15 |
Products named: VRAYLAR, Rybelsus, NURTEC ODT, QULIPTA, XIFAXAN, The Cologuard Plus Collection Kit, NEXLETOL, Ozempic.
Industry payments across MS — which companies pay providers there.
